Travere Therapeutics Inc (NAS:TVTX)
$ 6.245 -0.315 (-4.8%) Market Cap: 475.43 Mil Enterprise Value: 461.62 Mil PE Ratio: 0 PB Ratio: 6.44 GF Score: 58/100

Travere Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 10, 2021 / 04:30PM GMT
Release Date Price: $27.51 (+0.40%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Okay. Good morning, and welcome to day 2 of the Barclays Global Healthcare Conference.

My name is Carter Gould, Senior Biopharma Analyst here at Barclays, and it's my pleasure to welcome Travere Therapeutics up next.

Representing the company is CEO, Eric Dube. The company is really entering what we've called a defining period over the next, call it, 6 to 9 months. We recently initiated on Travere and they've had some positive data. Their key drug sparsentan in an initial indication and are engaging with regulators and other studies on the horizon. So with that, Eric, welcome, and thank you for joining us today.

Eric M. Dube
Travere Therapeutics, Inc. - President, CEO & Director

Absolutely. Thank you, Carter, and thank you to Barclays for hosting us today.

Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

We were just talking before it's fitting with World Kidney Day set for tomorrow.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot